AGP Executive Report

Health Technology: Siemens plans to send a healthcare delegation to Pakistan to pursue agreements on training and technology; the talks signal possible cooperation, not completed projects. Cancer Research: New ESMO data show durvalumab plus enfortumab vedotin improved event-free and overall survival in muscle-invasive bladder cancer patients unable or unwilling to receive cisplatin. Another study found apalutamide plus hormone therapy improved event-free survival in high-risk prostate cancer. Coverage Costs: Employer health plans are getting pricier: workers’ average annual contribution for family coverage rose 9% to $7,471, while average premiums reached $28,303, according to KFF. Drug Supply: Pakistan faces a shortage of imported rapid-acting insulin after a factory upgrade halted supplies; alternatives cost at least 20% more, while delayed price approvals have also disrupted access to essential medicines. Industry Growth: Ghana’s presidential candidate Mahamudu Bawumia discussed expanding local drug production and streamlining regulation with the Pharmaceutical Society of Ghana, pitching the country as a regional manufacturing hub.

Industrial Safety: Telangana’s human rights commission is seeking a report after a suspected chloroform leak at a pharmaceutical plant killed two workers and hospitalized six; three remain under treatment. Measles: U.S. cases have reached 4,588 this year, more than double 2025’s total, with Pennsylvania reporting 1,338 cases. About 96% nationally involve people who are unvaccinated or whose status is unknown. Coverage and Care: Humana and UnitedHealthcare are ending Medicare Advantage plans for about 1 million seniors next year. Separately, a Commonwealth Fund survey found 11.2% of working-age Americans were uninsured in 2026, while half delayed or skipped care because of cost. Clinical Research: AstraZeneca plans to invest $50 million in about 30 Abu Dhabi trials focused on cardiovascular, kidney and metabolic diseases. At ESMO, BMS’s antibody-drug conjugate cut progression or death risk by 59% versus chemotherapy in advanced breast cancer; GSK reported a 62% response rate for its ovarian cancer candidate, with severe treatment-related side effects in 71% of patients. Devices and Workforce: Edwards won FDA approval to use its Pascal system for tricuspid valve repair. CMS also launched a $275 million initiative offering eligible nursing-home nurses up to $40,000 in loan repayment or a $10,000 stipend.

Cancer Advances: New melanoma-vaccine results from Moderna and Merck showed 42% fewer recurrences and 38% less distant spread after surgery, drawing praise from oncologists even as the companies’ shares fell. ESMO also featured promising pancreatic-cancer data for daraxonrasib and activity for pembrolizumab plus chemotherapy in neuroendocrine prostate cancer. Flu Watch: Flu is rising early in parts of North America, and a CDC tool now tracks local trends in flu, COVID-19 and RSV. Researchers say a flu mutation first detected in Japan may be contributing to the early surge, though its role remains uncertain. Point-of-Care Screening: IIT Bombay researchers developed a low-cost blood-smear device designed to screen for anaemia and sickle cell disease using a drop of blood. Treatment Updates: The FDA approved a subcutaneous induction option for risankizumab in Crohn’s disease; trial results also showed fewer relapses with remibrutinib than teriflunomide in relapsing MS. Access and Costs: Five major companies pledged faster electronic prior authorizations, while a proposed US expansion of investment restrictions to biotechnology could affect cross-border research and drug development.

Drug Supply: Dr Reddy’s has introduced two more generic semaglutide brands in India after an impurity issue halted supplies of its original Obeda injection. US Manufacturing: Eli Lilly broke ground on a $6.5 billion Houston plant focused on oral GLP-1 medicines, including its obesity treatment orforglipron. Cancer Care: NICE will fund five AI tools to help NHS radiologists spot prostate cancer on MRI scans while further real-world data are collected. Patient Safety: India has ordered hospitals to stop reusing single-use medical devices, citing infection risks and improper charges to patients. Cancer Research: New melanoma trial analyses found lower recurrence and metastasis risks with Merck and Moderna’s personalized mRNA vaccine combined with pembrolizumab. Biotech Policy: A proposed US expansion of investment restrictions to Chinese biotech could affect deals and access to drug-development technologies.

Cancer Advances: Merck and Moderna reported that adding their personalized mRNA therapy to Keytruda cut recurrence risk by 42% in resected melanoma; results will be presented at ESMO. The FDA also granted Keytruda traditional approval for certain TMB-high solid tumors. New Drug Approvals: The FDA approved GSK and Ionis’ Hibsago, an antisense treatment for chronic hepatitis B, and granted AstraZeneca’s Ultomiris accelerated approval for adults with IgA nephropathy. Biotech Policy: The U.S. proposed restrictions on American investment in Chinese biotech, potentially complicating drugmakers’ growing partnerships with Chinese innovators. Data Security: Quest Diagnostics reported unauthorized access to its lab-services platform; some patient records may have been accessed, but the number is not yet known. Care Costs: Employer family health premiums averaged $28,303 in 2026, up 5% from last year.

Healthcare Data: Synology says demand for its storage systems from Malaysian healthcare and government organizations is driving strong sales growth. The company urged providers to test backups against ransomware, accidental deletion and insider threats. Clinical Trials: FDA and industry experts explored selective safety-data collection in trial scenarios, aiming to reduce research burdens while maintaining patient safeguards. AI in Drug Development: Boehringer Ingelheim and Microsoft will study digital patient models and trial simulations that could make studies more efficient and help therapies reach patients sooner. Rural Care: India’s CureBay raised ₹100 crore to expand its technology-enabled rural clinics and develop AI tools for screening and clinical decisions. Infectious Disease: France reported the first known human Shamonda virus case, ending in the death of a severely immunocompromised patient; authorities say there is no known risk to the public. Remote Monitoring: A proposed Medicare rule could restrict reimbursement when outside technology companies support remote patient monitoring, potentially limiting access for rural patients with chronic conditions.

Hepatitis B: The FDA approved GSK’s Hibsago (bepirovirsen), the first antisense treatment for chronic hepatitis B. In trials, 19% of patients achieved a functional cure after six months, compared with none on placebo. Women’s Health: An observational study linked fezolinetant to improved mild depression and anxiety symptoms in women with menopausal hot flashes. It is not approved to treat either condition, and researchers say it’s unclear whether mood benefits are direct or tied to hot-flash relief. Outbreak Watch: Nigeria confirmed an Ebola case, prompting increased surveillance and contact tracing, with WHO support. Drug Access: A new report says median net launch prices for new medicines rose 35% from 2022 to 2025, reaching $257,000; it also found many prescriptions go unfilled after coverage rejections. Diabetes Prevention: International guidance backs screening all children for early-stage type 1 diabetes, since most new cases occur in children with no family history.

Treatment Advances: Rusfertide improved hematocrit control and reduced phlebotomy in polycythemia vera, with reported gains in fatigue and symptom burden. In a phase 2 C. difficile trial, LMN-201 plus antibiotics achieved an 83.3% global cure rate versus 36.4% with placebo; recurrence was 9.1% versus 55.6%. Precision Medicine: Prime editing repaired a GATA2 mutation in patient-derived stem cells in preclinical research. An Indian AI-based breast cancer test aims to help identify early-stage patients who may not benefit from chemotherapy. AI in Care: Cancer specialists say AI can help identify people eligible for lung screening, but human counseling and representative training data remain essential. Public Health: Nigeria confirmed an Ebola case, with health authorities tracing 44 contacts as an outbreak spreads in the region. Industry & Access: Median net launch prices for new drugs rose 35% from 2022 to 2025, reaching $257,000, keeping affordability in focus. Medtech executives also expect more small acquisitions and portfolio cuts.

Outbreak Watch: Nigeria confirmed one Ebola case in Abuja; 44 contacts have been identified, and Africa CDC is urging urgent international support to contain the outbreak. Health Inequality: A major WHO analysis finds social and economic disadvantages shape people’s exposure to non-communicable diseases and access to prevention and care; these diseases account for three-quarters of deaths worldwide. Cancer Care: A new UK consensus aims to reduce postcode-based gaps by setting out local and regional services for people with cancer. The FDA also granted accelerated approval to Jemperli for certain locally advanced rectal cancers. Drug Access and Safety: The FDA approved bepirovirsen, the first antisense treatment for chronic hepatitis B, for some adults. Separately, compounded tirzepatide vials were recalled because their sterility could not be assured. Pharma Deals: Roche and Hansoh announced a cancer-drug partnership worth up to $15 billion, focused on antibody-drug conjugates.

Digital Health: FDA guidance clarifies when drug-connected apps count as labeling, prompting sponsors to plan clinical testing and software updates earlier. COPD Care: A hospital program combining discharge checklists, inhaler education, follow-up support and rehab referrals cut 30-day readmissions from 27.9% to 18.2%. Clinical Trials: Optum and Syneos Health are teaming up on a data- and AI-supported model to improve trial planning, recruitment and operations. Prescribing Ethics: A review of 93 studies linked pharmaceutical gifts and payments with more inappropriate prescribing, renewing concerns about industry influence on treatment choices. Drug Safety: One in six children taking GLP-1 drugs developed a nutritional deficiency within a year, but only 5% received nutrition counseling in the first month. Industry Deals: Merck is buying Silence Therapeutics for $1.3 billion to expand its RNA drug pipeline, while Roche struck a $15 billion deal with Hansoh for antibody-drug candidates.

Cancer Screening: India’s Rajiv Gandhi Centre for Biotechnology won a ₹7 crore grant to develop an automated blood test for early cervical cancer detection. The device is still in development and will need validation. Cancer Treatment: The FDA granted accelerated approval to Jemperli for adults with stage II or III MSI-H/dMMR locally advanced rectal cancer, offering a new option for a biomarker-defined group. Heart and Kidney Health: A review found intensive blood-pressure lowering cut major cardiovascular events by 15% per 10 mm Hg reduction, with similar benefits in people with and without chronic kidney disease. It did not prevent kidney failure and increased the risk of sustained kidney-function decline. Flu Prevention: Spokane County reported its first flu-related death of the season; health officials urge vaccination, recommended for everyone aged 6 months and older. Separately, an EU advisory panel backed extending AstraZeneca’s H5N1 vaccine eligibility to adults. Brain Health: In a small study, 20 minutes of aerobic exercise helped preserve memory after 30 hours without sleep, with results comparable to a 90-minute nap.

Diabetes Care: The FDA cleared Sequel’s Twiist automated insulin-delivery system for adults with insulin-treated Type 2 diabetes. In a 13-week study, users spent more time in the target blood-sugar range. Drug Development: An FDA pilot aims to cut delays in first-in-human trials by letting qualified research institutions coordinate key steps; the first cohort will be small. Rare Disease: Bitopertin met all primary and secondary endpoints in a Phase 3 trial for erythropoietic protoporphyria, a rare condition that causes painful reactions to light. The drug remains investigational. Cancer Access: India will cap trade margins on 137 cancer medicines starting Nov. 9, a move expected to lower costs for some patients. Biotech Investment: Germany’s sector is drawing major pharma partnerships and acquisitions, including Gilead’s reported €4.48 billion purchase of Tubulis.

Cancer Drug Access: India has capped trade margins at 30% for 137 cancer medicines, with some prices expected to fall by up to 70% from Nov. 9; actual reductions will vary. Healthcare Capacity: Tata Trusts plans 40–50 not-for-profit hospitals and a five-year push to expand primary care and train frontline workers, though locations and timing are not yet set. Drug Development: Novartis has ended its phase 2 Fabhalta trial for lupus nephritis, citing strategic considerations, while upcoming patent expiries are driving biosimilar companies to expand their pipelines. Emergency Care: Alberta is launching physician-led triage to begin assessments and tests earlier for patients waiting in emergency departments. Respiratory Health: CHEST 2026 analyses linked sputum purulence with bronchiectasis activity and found mepolizumab reduced steroid exposure in eosinophilic COPD; separate observational research associated chronic proton-pump inhibitor use with more asthma exacerbations. Fertility Advice: An infertility specialist recommends addressing modifiable habits, including smoking and diet, before treating IVF as the first step.

HIV Care: Updated HHS guidelines recommend dolutegravir/lamivudine for some adults regardless of viral load, while a newly approved combination remains under review. Youth Mental Health: A new report says one in six teens has anxiety, with many also experiencing suicidal thoughts. Menopause: A Finnish study of 2,632 women linked reaching late perimenopause or menopause by age 46 with more anxiety and depressive symptoms; it does not establish cause and effect. Infection and Gut Health: Among hospitalized blood-cancer patients, higher sugar intake around antibiotic treatment was associated with greater loss of beneficial gut bacteria and growth of potentially harmful microbes. Outbreak Watch: The Ebola outbreak in the Democratic Republic of Congo has topped 9,235 confirmed cases, while Kenya has reported a third case. Drug Access: India will cap trade margins on 137 cancer drugs at 30%, with revised prices due from Nov. 9. Healthcare Staffing: UPMC Enterprises invested in VeloSource to expand an AI-enabled clinician staffing platform as health systems face persistent workforce shortages.

Cancer Drug Costs: India has capped trade margins at 30% for 137 cancer medicines, with revised prices due Nov. 9 and some retail prices expected to fall by up to 70%. GLP-1 Research: A review of clinical trials found semaglutide and tirzepatide were linked to reduced sleep-apnea severity and cardiovascular risk; weight loss explained only part of some benefits. Ebola Watch: The DRC outbreak has passed 9,200 confirmed cases, according to the CDC, which reports no U.S. cases linked to the outbreak and says risk to the American public remains low. New Epilepsy Treatments: Morocco’s Sothema won approval for three cannabis-based epilepsy medicines, though launch dates and prices have not been announced. Child Health: Researchers detected an average of 31 pesticide-related compounds in urine samples from each of 187 children, raising questions about exposure to chemical mixtures. Antibiotic Stewardship: A new review says AI may help flag patients for antibiotic review, but incomplete records and prescribing patterns limit its reliability.

Cancer Drug Costs: India’s NPPA capped trade margins at 30% on 137 commonly used cancer drugs, with revised prices taking effect Nov. 9; Keytruda is excluded. Health Workforce: Nepal added 418 government medical-education seats, including 110 for medical degrees and 210 for nursing. Industry Safety: A fire broke out in the herbal division of a medicine factory in Bangladesh; no injuries were reported initially. Infectious Disease: US measles cases reached 4,410, including five confirmed deaths in Pennsylvania, while WHO urged vigilance after a second Ebola case in Kenya. Treatment Advances: EU regulators backed Foundayo, an oral medicine for obesity and type 2 diabetes. In a small trial, a long-acting HIV drug combination kept all 46 participants virally suppressed. Care Access: New findings suggest glucose monitors may benefit people with type 2 diabetes who do not use insulin.